A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
Open Access
- 1 October 2013
- journal article
- phase i-studies
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 31 (5), 1182-1191
- https://doi.org/10.1007/s10637-013-0001-5
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic responseLeukemia, 2012
- Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic PropertiesCancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Rational targeting of Notch signaling in cancerOncogene, 2008
- Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemiaNature Medicine, 2007
- High-level JAG1 mRNA and protein predict poor outcome in breast cancerLaboratory Investigation, 2007
- Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimusEuropean Journal of Cancer, 2006
- High-level Coexpression of JAG1 and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with Poor Overall SurvivalCancer Research, 2005
- Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2004
- Notch Signaling: Cell Fate Control and Signal Integration in DevelopmentScience, 1999